Manelimab
Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research.
For research use only. We do not sell to patients.
- CAS No.: 2168561-26-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 lambda2
Human
B7-H1/PD-L1/CD274
Manelimab is a PD-L1 inhibitory antibody that blocks the interaction between PD-L1 and PD-1. When used in combination with the IL-10-Fc immunocytokine, it is applied to anti-tumor related studies in various tumor models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2168561-26-8
-
SMILES
[Manelimab]
-
Synonyms
BCD-135
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Manelimab Related Classifications
HY-P99723 Related Classifications
Powered by Bioz